A cute c oronary t reatment and i ntervention o utcomes n etwork
Download
1 / 25

why action - PowerPoint PPT Presentation


  • 174 Views
  • Uploaded on

“An ACC and AHA? Effort to Improve MI Care” Eric Peterson, MD, MPH, FACC, FAHA Professor of Medicine Director of CV Research Duke Clinical Research Institute. A cute C oronary T reatment and I ntervention O utcomes N etwork. Background.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'why action' - Samuel


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
A cute c oronary t reatment and i ntervention o utcomes n etwork l.jpg

“An ACC and AHA? Effort to Improve MI Care”

Eric Peterson, MD, MPH, FACC, FAHA

Professor of Medicine

Director of CV Research

Duke Clinical Research Institute

Acute

Coronary

Treatment and

Intervention

Outcomes

Network


Background l.jpg
Background

  • Outcomes of STEMI and NSTEMI can be altered with evidence-based, timely, and safe care.

  • Yet, studies have shown ACS care is sub-optimal

    • Gaps between guideline recommendations and practice

    • Significant care delays (reperfusion Rx in STEMI)

    • Care disparities (age, gender, race, insurance)

    • Paradoxical care (failure to treat those most in need)

    • Safety concerns (excessive dosing)


Acute medications stemi vs nstemi use l.jpg
Acute Medications STEMI vs NSTEMI Use

CRUSADE DATA: July 1, 2005 – June 30, 2006 (n=31,665)


Timely reperfusion among stemi patients l.jpg
Timely Reperfusion among STEMI Patients

Q2 2006 CRUSADE STEMI data


Safety concerns frequency of excessive antithrombotic dosing l.jpg
Safety Concerns: Frequency of Excessive Antithrombotic Dosing

Alexander KA, et al. JAMA 2005;294:3108-3116


Why is action needed l.jpg
Why is ACTION Needed

  • Participation in CMS Metrics is just not enough

    • Fails to capture newer effective therapies (e.g, Class I ACC/AHA guideline treatments)

    • Doesn’t collect important safety information (dosing)

    • Limited data on timing of therapies

    • Lack patient outcomes

    • Limited performance feedback

  • Broad QI Interventions increasing all aspects of ACS care is needed to improve patient outcomes


Provider led qi works l.jpg

Clinical Trials

Concept

Guidelines

Provider Led

Quality Improvement

Outcomes

Performance

Indicators

Safe, Effective,

Long-term Use

Measurement

Provider Led QI Works!

  • Participation in provider-led quality improvement (QI) efforts can improve ACS care!

    • ACC-GAP

    • AHA GWTG

    • NRMI, CRUSADE

  • Means of QI

    • Feedback

    • Motivated local champions

    • Collaborative sharing of best practices


Slide8 l.jpg

GAP Results: Changing Practice

**

93%

92%

100%

86%

89%

84%

80%

75%

*

80%

68%

65%

53%

60%

40%

20%

0%

(267) (406) (106) (146) (139) (173) (159) (226) (112) (209)

ASA BB ACE SMOKING CHOL RX

* p < 0.05

** p < 0.01

PRE POST


Slide9 l.jpg

1

0.9

0.8

0.7

0.6

Baseline

Proportion of Patients

0.5

4-6 Months

0.4

9-12 Months

0.3

0.2

0.1

0

ACE

ASA

BP Control

Rehab/ Ex

Beta-blocker

Smoking Cessation

Lipid Lowering

LDL Measurement

New England AHA GWTG Pilot Trial 12 Month Results


Composite adherence trends in crusade l.jpg
Composite Adherence Trends in CRUSADE

Quarter 1, 2002 through Quarter 2, 2006


Slide11 l.jpg

Association Between Overall

Guidelines Adherence and Mortality

Every 10%  in guidelines adherence 

10%  in mortality (OR=0.90, 95% CI: 0.84-0.97)

Peterson et al, JAMA 2006;295:1863-1912


The action registry l.jpg
The ACTION Registry

  • Represents the merger of the nation’s premier ACS registries:

    • NRMI (National Registry of Myocardial Infarction)

    • CRUSADE

    • ? Soon AHA GWTG CAD

  • Unified under the leadership and support of NCDR™ :

    • Guidelines, performance indictor, and data standard alignment

    • Clinical/Technical/contract Support

    • Training and orientation


Goals of the action registry l.jpg
Goals of the ACTION Registry

  • The nation’s ACS surveillance system

    • Assess characteristics, treatments, and outcomes of patients hospitalized with STEMI and NSTEMI

  • Optimize the care and outcomes of ACS patients

    • Implement ALL evidence-based guideline recommendations in clinical practice

    • Assure that the right things are done right (safe and timely).

  • Facilitate efforts to improve ACS care quality & safety via novel QI improvement methods


Slide14 l.jpg

Registry

  • No charge for participation

  • Support provided by

    • Genentech

    • BMS and Sanofi

    • Schering Plough

  • Data elements

    • Consistent w AHA/ACC

  • Data submission

    • EDC system

    • Soon multivendor


Current action site distribution l.jpg
Current ACTION Site Distribution

Active Sites = 290

WA

(12)

ME

(1)

VT (0)

ND

(1)

MT

(1)

MI

NH (1)

MN

(5)

NY

(10)

OR

(6)

MA (1)

WI

(6)

SD

(1)

RI (0)

ID

(1)

MI

(14)

WY

(0)

CT (2)

PA

(26)

IA

(7)

NJ (6)

NE (4)

OH

(22)

DE (0)

NV

(0)

IL

(18)

IN

(12)

WV

(1)

MD (11)

VA

(11)

UT

(0)

CO

(7)

KY

(2)

MO

(8)

KS

(5)

DC (0)

CA

(15)

NC

(17)

TN

(8)

SC

(3)

OK

(2)

AR

(1)

AZ

(3)

NM

(0)

AL

(3)

GA

(8)

MS

(5)

LA

(2)

TX

(11)

FL

(9)

AK

(1)

HI (0)

Last updated: 1/4/07



Complexity of acs patients stemi vs nstemi l.jpg
Complexity of ACS PatientsSTEMI vs. NSTEMI

ACTION/CRUSADE DATA: July 1, 2006 – June 30, 2007


In hospital outcomes stemi vs nstemi l.jpg
In-Hospital OutcomesSTEMI vs. NSTEMI

*Transfusion among non-CABG patients

ACTION/CRUSADE DATA: July 1, 2006 – June 30, 2007


Acute medications stemi vs nstemi l.jpg
Acute Medications STEMI vs NSTEMI

ACTION/CRUSADE DATA: July 1, 2006 – June 30, 2007

STEMI (n=11,854) NSTEMI (n=26,956)


Slide20 l.jpg

STEMI – Timing of Reperfusion

ACTION/CRUSADE DATA: July 1, 2006 – June 30, 2007 (n=11,854)

DTB = 1st Door to Balloon

DTN = 1st Door to Needle for Lytics


Discharge medications stemi vs nstemi l.jpg
Discharge Medications STEMI vs NSTEMI

* Ideal Patients

ACTION/CRUSADE DATA: July 1, 2006 – June 30, 2007

STEMI (n=11,854) NSTEMI (n=26,956)


Discharge interventions stemi vs nstemi l.jpg
Discharge InterventionsSTEMI vs. NSTEMI

ACTION/CRUSADE DATA: July 1, 2006 – June 30, 2007

STEMI (n=11,854) NSTEMI (n=26,956)


Action qi tool development l.jpg
ACTION QI Tool Development

  • Quarterly Feedback reports

  • Individualized Gap analysis

  • On-line Real time summaries

  • QI tool kits

  • D2B tool kits

  • Monthly Web-casts

  • Regional Group Meetings

  • TAKE ACTION™ Campaign


How to join l.jpg
How to Join

  • Download the enrollment file from www. ncdr.com

  • Complete your enrollment packet and submit the materials to the NCDR

  • Receive Welcome Kit

  • Complete online tool tutorial

    Questions:

    Call 800-257-4737

    Email [email protected]


Thanks l.jpg
Thanks

Questions???


ad